CHEK1 and melanoma: Preclinical studies showed that melanoma cells with high levels of endogenous replicative stress are particularly susceptible to CHK1 inhibitors (AR323, AR678, GNE-323 and GDC-0575) in vitro and in vivo in xenograft models [74,76].